Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;53(1):89-94.
doi: 10.1007/s11262-016-1396-9. Epub 2016 Oct 6.

Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015-2016 season in Japan

Affiliations

Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015-2016 season in Japan

Akinobu Hibino et al. Virus Genes. 2017 Feb.

Abstract

We report five cases of community- and hospital-acquired infections with oseltamivir- and peramivir-resistant A(H1N1)pdm09 viruses possessing the neuraminidase (NA) H275Y mutation during January-February 2016 in Japan. One case was hospitalized and was receiving oseltamivir for prophylaxis. The remaining four cases were not taking antiviral drugs at the time of sampling. These cases were geographically distant and epidemiologically unrelated. The five viruses showed ~300-fold rise in IC50 values against oseltamivir and peramivir, defined as highly reduced inhibition according to the WHO definition. Overall, the prevalence of the H275Y A(H1N1)pdm09 viruses was 1.8 % (5/282). The resistant viruses possessed the V241I, N369 K, and N386 K substitutions in the NA that have been previously reported among A(H1N1)pdm09 to alter transmission fitness. Analysis of Michaelis constant (Km) revealed that two of the isolates had reduced NA affinity to MUNANA, while the other three isolates displayed a slightly decreased affinity compared to the sensitive viruses. Further studies are needed to monitor the community spread of resistant viruses and to assess their transmissibility.

Keywords: Antiviral drug susceptibility; Community transmission; Enzymatic property; Influenza virus A(H1N1)pdm09; Neuraminidase; Oseltamivir resistant.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical Standards Conflict of Interest: Reiko Saito received research grants from Shionogi Co., Ltd. Other authors, Akinobu Hibino, Hiroki Kondo, Hironori Masaki, Yoshinari Tanabe, Isamu Sato, Nobuhiro Takemae, Takehiko Saito, and Hassan Zaraket, declare that they have no conflict of interest. Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Niigata University Ethics Committee (H23-1178). Informed consent Informed consent was obtained from all individual participants included in the study.

Figures

Fig. 1
Fig. 1
Phylogenetic analysis of the hemagglutinin (a) and neuraminidase gene (b) of the five H275Y mutant influenza A(H1N1)pdm09 strains isolated in Niigata and Nagasaki, Japan in January to February 2016. Multiple alignment was constructed by the neighbor-joining method with MEGA, version6. Bootstrap value determined for 1000 interactions. Only values of greater than 70 % are shown. The H275Y mutant strains are shown in red, and those detected in the 2015/2016 season are indicated in closed circle. The sensitive strains that were used for enzymatic property measurement (Km and Vmax) are colored blue. Reference sequences of A(H1N1)pdm09 strains downloaded from the GenBank and GISAID EpiFlu Database (www.gisaid.org.). The amino acid substitutions relative to the A/California/07/2009 strain are shown in the phylogenetic tree (Color figure online)

Similar articles

Cited by

References

    1. World Health Organization Wkly Epidemiol. Rec. 2012;87:369–374. - PubMed
    1. Hurt AC. Curr. Opin. Virol. 2014;8C:22–29. doi: 10.1016/j.coviro.2014.04.009. - DOI - PubMed
    1. McKimm-Breschkin JL. Influenza Other Respir. Viruses. 2013;7:25–36. doi: 10.1111/irv.12047. - DOI - PMC - PubMed
    1. Zaraket H., and Saito R., Current Treatment Options in Infectious Diseases, in press - PMC - PubMed
    1. Huang W, Li X, Cheng Y, Tan M, Guo J, Wei H, Zhao X, Lan Y, Xiao N, Wang Z, Wang D, Shu Y. Virol J. 2015;12:96. doi: 10.1186/s12985-015-0317-1. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources